Eucrisa approved as atopic dermatitis treatment by FDA
Eucrisa is a non-steroidal topical phosphodiesterase-4 (PDE-4) inhibitor developed to treat mild-to-moderate atopic dermatitis (AD) in patients ages two and older.
“The approval of Eucrisa is great news for the children and adults suffering from mild to moderate eczema, a community that has not had a new prescription treatment for more than 10 years,” Pfizer Innovative Health Group President Albert Bourla said. “This is also an important milestone for Pfizer as we continue to build on our heritage in Inflammation and Immunology by offering innovative treatment options to patients who need them.”
Eucrisa is the first and currently only non-steroidal topical monotherapy inhibiting the PDE-4 enzyme in the skin.
“I’m delighted to have a new option for my patients with mild to moderate atopic dermatitis,” Northwestern University Feinberg School of Medicine Professor of Pediatrics Dr. Amy Paller, a clinical trial investigator, said. “The results seen in these pivotal phase 3 studies show the efficacy and safety of Eucrisa as a steroid-free treatment option for people as young as two living with mild to moderate atopic dermatitis.”
Organizations in this story
Pfizer 235 E 42nd St New York, NY 10017-5703